Advertisement
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on theoral and nasal delivery of large-market peptide drugs. Due to the size of theworldwide osteoporosis market, Unigene is targeting its initial efforts ondeveloping calcitonin and PTH-based therapies. Fortical(r), Unigene's nasalcalcitonin product for the treatment of postmenopausal osteoporosis, receivedFDA approval and was launched in August 2005. Unigene has licensed the U.S.rights for Fortical(r) to Upsher-Smith Laboratories, worldwide rights for itsoral PTH technology to GlaxoSmithKline and worldwide rights for itscalcitonin manufacturing technology to Novartis. Unigene's patented oraldelivery technology has successfully delivered, in preclinical and/orclinical trials, various peptides including calcitonin, PTH and insulin.Unigene's patented manufacturing technology is designed to cost-effectivelyproduce peptides in quantities sufficient to support their worldwidecommercialization as oral or nasal therapeutics. For more information aboutUnigene, call (973)-882-0860 or visit www.unigene.com. For information aboutFortical, visit http://www.fortical.com.
Advertisement
Safe Harbor statements under the Private Securities Litigation Reform Actof 1995: This press release contains forward-looking statements as defined inSection 27A of the Securities Act of 1933, as amended, and Section 21E of theSecurities Exchange Act of 1934, as amended. Such forward-looking statementsare based upon Unigene Laboratories, Inc.'s management's currentexpectations, estimates, beliefs, assumptions, and projections aboutUnigene's business and industry. Words such as "anticipates," "expects,""intends," "plans," "predicts," "believes," "seeks," "estimates," "may,""will," "should," "would," "potential," "continue," and variations of thesewords (or negatives of these words) or similar expressions, are intended toidentify forward-looking statements. In addition, any statements that referto expectations, projections, or other characterizations of future events orcircumstances, including any underlying assumptions, are forward-lookingstatements. These forward-looking statements are not guarantees of futureperformance and are subject to certain risks, uncertainties, and assumptionsthat are difficult to predict. Therefore, our actual results could differmaterially and adversely from those expressed in any forward-lookingstatements as a result of various risk factors. These risks and uncertaintiesinclude the risks associated with the effect of changing economic conditions,trends in the products markets, variations in Unigene's cash flow, marketacceptance risks, technical development risks and other risk factors detailedin Unigene's Securities and Exchange Commission filings.Contact: Warren P. Levy President and CEO Unigene Laboratories, Inc. 110 Little Falls Road Fairfield, NJ 07004 Tel.: +1-(973)-882-0860 Fax: +1-(973)-227-6088 E-Mail: [email protected]
SOURCE Unigene Laboratories Inc.
